Latest News

The recombinant factor VIII (FVIII) therapy BAY 94-9027 demonstrated long-term safety and efficacy at reducing bleeds in pediatric patients with severe hemophilia A, according to results of a long-term analysis published in the journal Haemophilia. The analysis was the extension study of the phase 3 PROTECT VIII Kids trial (ClinicalTrials.gov Identifier: NCT01775618),...
LA JOLLA, Calif. — Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad...
1. SYMPTOMS – “Mommy, I’m afraid. Tell me what to do.” The child’s mother looked up at her 8-year-old daughter. “It’s going to be O.K.,” she said. “Just go get some help.” The woman watched as her daughter left the public bathroom, where she now lay. She and her daughter...
Tokyo, Japan – Researchers from Tokyo Metropolitan University have studied pancreatic islet cell loss in people with no previous pancreatic problems. They identified key trends in the types of cells lost due to islet cell loss in different age groups and sexes, finding that ICL in the elderly population was...
Portland, OR – New research from Oregon Health & Science University suggests that people with multiple sclerosis, or MS, could benefit from a low-fat diet to improve the fatigue that’s a debilitating, and often-underappreciated, symptom of the condition. The study, published online Wednesday in the Multiple Sclerosis Journal, is the latest in...
Saint Louis, Missouri – In Alzheimer’s disease and related dementias, cognitive decline is driven by the overaccumulation of a normal brain protein known as tau. Wherever tau builds up, nearby brain tissue starts to degenerate and die. Now, researchers at Washington University School of Medicine in St. Louis have found...
New Orleans, LA – Research led by Ashok Aiyar, PhD, Associate Professor of Microbiology at LSU Health Sciences Center New Orleans, showing that a single gene can control growth in cancers related to the Epstein-Barr virus and that existing therapeutics can inactivate it, will be published in the June 12,...
NEW YORK, NY – A Ludwig Cancer Research study has discovered how a lipid molecule found at high levels within tumors undermines the anti-cancer immune response and compromises a recently approved immunotherapy known as adoptive cell therapy (ACT) using tumor infiltrating lymphocytes, or TIL-ACT. In this individualized cell therapy, TILs—CD8+...